Patent(s) and the Corresponding Patented Drug(s) |
Top |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US9206139 |
Title |
Aggrecanase inhibitors |
Abstract |
The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D0G1LL |
Drug Info
|
IC50 = 2 nM |
Click to Show More |
[1] |
2
|
D0UM5R
|
Drug Info
|
IC50 = 7 nM
|
[1] |
3
|
D0N6ZA
|
Drug Info
|
IC50 = 14 nM
|
[1] |
Patent ID |
US9206139 |
Title |
Aggrecanase inhibitors |
Abstract |
The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D0G1LL |
Drug Info
|
IC50 = 2 nM |
Click to Show More |
[1] |
2
|
D0UM5R
|
Drug Info
|
IC50 = 7 nM
|
[1] |
3
|
D0N6ZA
|
Drug Info
|
IC50 = 14 nM
|
[1] |
Patent ID |
US9206139 |
Title |
Aggrecanase inhibitors |
Abstract |
The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof. |
Applicant(s) |
Eli Lilly and Company |
Representative Drug(s) |
D0G1LL |
Drug Info
|
IC50 = 2 nM |
Click to Show More |
[1] |
2
|
D0UM5R
|
Drug Info
|
IC50 = 7 nM
|
[1] |
3
|
D0N6ZA
|
Drug Info
|
IC50 = 14 nM
|
[1] |